Melissa K. Accordino, MD, MS, discusses the utility of liquid biopsies in breast cancer.
Melissa K. Accordino, MD, MS
Advertisement
Articles by Melissa K. Accordino, MD, MS
Melissa K. Accordino, MD, MS, discusses the findings of the PEARL trial in hormone receptor-positive, HER2-negative metastatic breast cancer.
Melissa K. Accordino, MD, MS, discusses the utility of CDK4/6 inhibitors in hormone receptor–positive, HER2-negative breast cancer.
Advertisement
Latest Updated Articles
Dr. Accordino on the Utility of CDK4/6 Inhibitors in HR+/HER2Published: February 6th 2020 | Updated:
Dr. Accordino on Data From the PEARL Trial in HR+/HER2- Metastatic Breast CancerPublished: April 8th 2020 | Updated:
Dr. Accordino on Utility of Liquid Biopsies in Breast CancerPublished: May 9th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
Nuvisertib Yields Strong Safety, Promising Efficacy in R/R Myelofibrosis
5